Cargando…

2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates

BACKGROUND: Plazomicin, a novel aminoglycoside, is active against carbapenem-resistant Enterobacteriaceae (EB) and is not inhibited by most aminoglycoside modifying enzymes that affect gentamicin and tobramycin. We investigated the activity of plazomicin against resistant EB clinical isolates and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepak, Alexander, Grajcevci, Luriane, Banach, Joyce, Meyer, Katherine, Chen, Derrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810740/
http://dx.doi.org/10.1093/ofid/ofz360.1842
_version_ 1783462318379630592
author Lepak, Alexander
Lepak, Alexander
Grajcevci, Luriane
Banach, Joyce
Meyer, Katherine
Chen, Derrick
author_facet Lepak, Alexander
Lepak, Alexander
Grajcevci, Luriane
Banach, Joyce
Meyer, Katherine
Chen, Derrick
author_sort Lepak, Alexander
collection PubMed
description BACKGROUND: Plazomicin, a novel aminoglycoside, is active against carbapenem-resistant Enterobacteriaceae (EB) and is not inhibited by most aminoglycoside modifying enzymes that affect gentamicin and tobramycin. We investigated the activity of plazomicin against resistant EB clinical isolates and compared disk diffusion (DD) vs. gradient diffusion (GD) results. METHODS: EB isolates that were carbapenem resistant and/or resistant to both gentamicin and tobramycin were retrieved from the UW Health clinical isolate repository. Each isolate was tested against plazomicin using both DD (MAST Group Ltd. Plazomicin disk 30 µg) and GD (Liofilchem Plazomicin MIC Test Strip 0.16–256 µg/mL) methods according to manufacturer instructions and using FDA clinical breakpoints for interpretation. RESULTS: 51 isolates were tested: 21 E. coli, 9 P. mirabilis, 7 E. cloacae, 6 K. pneumoniae, 3 K. oxytoca, 3 S. marcescens, 1 K. aerogenes, and 1 C. freundii. Specimen sites included: 29 blood, 8 urine, 8 soft tissue or bone, 5 intra-abdominal, and 1 sputum. Previous phenotypic AST results demonstrated 19 (37%) were CRE, of which 5 were also gentamicin and tobramycin resistant, and 32 (63%) were tobramycin and gentamicin resistant but carbapenem susceptible. Plazomicin zone diameters and minimal inhibitory concentrations (MIC) for all isolates are shown in the figure (data jittered to show frequency). There was a significant correlation between increased MIC and smaller zone diameters (Pearson coefficient −0.443, P = 0.001). However, while all 51 isolates were susceptible by DD breakpoints, only 46 (92%) were susceptible by GD breakpoints. All 5 discordant results were P. mirabilis which had an MIC of 4 µg/mL (intermediate) but zone diameters of 20–21 mm (susceptible). CONCLUSION: Concordance between plazomicin DD and GD susceptibility was only 92%. All 5 discordant results were P. mirabilis. Surveillance studies demonstrate >80% of P. mirabilis have MIC of 2–4 mg/L. Given the DD breakpoint is 16 mm, our data suggest DD was overly active in our sample set. Comparison of DD and GD to reference broth microdilution against a larger set of isolates is warranted to determine which method is optimal; however, our data suggest DD may result in categorical errors for P. mirabilis. [Image: see text] DISCLOSURES: Alexander Lepak, MD, Paratek Pharmaceuticals: Research Grant; Tetraphase Pharmaceuticals: Research Grant.
format Online
Article
Text
id pubmed-6810740
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68107402019-10-28 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates Lepak, Alexander Lepak, Alexander Grajcevci, Luriane Banach, Joyce Meyer, Katherine Chen, Derrick Open Forum Infect Dis Abstracts BACKGROUND: Plazomicin, a novel aminoglycoside, is active against carbapenem-resistant Enterobacteriaceae (EB) and is not inhibited by most aminoglycoside modifying enzymes that affect gentamicin and tobramycin. We investigated the activity of plazomicin against resistant EB clinical isolates and compared disk diffusion (DD) vs. gradient diffusion (GD) results. METHODS: EB isolates that were carbapenem resistant and/or resistant to both gentamicin and tobramycin were retrieved from the UW Health clinical isolate repository. Each isolate was tested against plazomicin using both DD (MAST Group Ltd. Plazomicin disk 30 µg) and GD (Liofilchem Plazomicin MIC Test Strip 0.16–256 µg/mL) methods according to manufacturer instructions and using FDA clinical breakpoints for interpretation. RESULTS: 51 isolates were tested: 21 E. coli, 9 P. mirabilis, 7 E. cloacae, 6 K. pneumoniae, 3 K. oxytoca, 3 S. marcescens, 1 K. aerogenes, and 1 C. freundii. Specimen sites included: 29 blood, 8 urine, 8 soft tissue or bone, 5 intra-abdominal, and 1 sputum. Previous phenotypic AST results demonstrated 19 (37%) were CRE, of which 5 were also gentamicin and tobramycin resistant, and 32 (63%) were tobramycin and gentamicin resistant but carbapenem susceptible. Plazomicin zone diameters and minimal inhibitory concentrations (MIC) for all isolates are shown in the figure (data jittered to show frequency). There was a significant correlation between increased MIC and smaller zone diameters (Pearson coefficient −0.443, P = 0.001). However, while all 51 isolates were susceptible by DD breakpoints, only 46 (92%) were susceptible by GD breakpoints. All 5 discordant results were P. mirabilis which had an MIC of 4 µg/mL (intermediate) but zone diameters of 20–21 mm (susceptible). CONCLUSION: Concordance between plazomicin DD and GD susceptibility was only 92%. All 5 discordant results were P. mirabilis. Surveillance studies demonstrate >80% of P. mirabilis have MIC of 2–4 mg/L. Given the DD breakpoint is 16 mm, our data suggest DD was overly active in our sample set. Comparison of DD and GD to reference broth microdilution against a larger set of isolates is warranted to determine which method is optimal; however, our data suggest DD may result in categorical errors for P. mirabilis. [Image: see text] DISCLOSURES: Alexander Lepak, MD, Paratek Pharmaceuticals: Research Grant; Tetraphase Pharmaceuticals: Research Grant. Oxford University Press 2019-10-23 /pmc/articles/PMC6810740/ http://dx.doi.org/10.1093/ofid/ofz360.1842 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lepak, Alexander
Lepak, Alexander
Grajcevci, Luriane
Banach, Joyce
Meyer, Katherine
Chen, Derrick
2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
title 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
title_full 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
title_fullStr 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
title_full_unstemmed 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
title_short 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
title_sort 2162. comparison of plazomicin disk diffusion vs. gradient diffusion susceptibility testing results against drug-resistant clinical enterobacteriaceae isolates
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810740/
http://dx.doi.org/10.1093/ofid/ofz360.1842
work_keys_str_mv AT lepakalexander 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates
AT lepakalexander 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates
AT grajcevciluriane 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates
AT banachjoyce 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates
AT meyerkatherine 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates
AT chenderrick 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates